

# Alessandro Pratesi

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6966815/publications.pdf>

Version: 2024-02-01

62

papers

1,438

citations

257450

24

h-index

361022

35

g-index

63

all docs

63

docs citations

63

times ranked

1459

citing authors

#	ARTICLE	IF	CITATIONS
1	Auranofin, Et <sub>3</sub> PAuCl, and Et <sub>3</sub> PAuI Are Highly Cytotoxic on Colorectal Cancer Cells: A Chemical and Biological Study. ACS Medicinal Chemistry Letters, 2017, 8, 997-1001.	2.8	91
2	Insights on the mechanism of thioredoxin reductase inhibition by Gold N-heterocyclic carbene compounds using the synthetic linear Selenocysteine containing C-terminal peptide hTrxR(488-499): An ESI-MS investigation. Journal of Inorganic Biochemistry, 2014, 136, 161-169.	3.5	88
3	Reactions of medicinally relevant gold compounds with the C-terminal motif of thioredoxin reductase elucidated by MS analysis. Chemical Communications, 2010, 46, 7001.	4.1	64
4	Replacement of the Thiosugar of Auranofin with Iodide Enhances the Anticancer Potency in a Mouse Model of Ovarian Cancer. ACS Medicinal Chemistry Letters, 2019, 10, 656-660.	2.8	64
5	ESI MS studies highlight the selective interaction of Auranofin with protein free thiols. Dalton Transactions, 2020, 49, 5906-5913.	3.3	57
6	Metallo therapeutics for COVID-19. Exploiting metal-based compounds for the discovery of new antiviral drugs. Expert Opinion on Drug Discovery, 2021, 16, 39-46.	5.0	53
7	Antiproliferative effects of two gold(I)-N-heterocyclic carbene complexes in A2780 human ovarian cancer cells: a comparative proteomic study. Oncotarget, 2018, 9, 28042-28068.	1.8	53
8	Reactions of Auranofin and Its Pseudohalide Derivatives with Serum Albumin Investigated through ESI-Q-TOF MS. Inorganic Chemistry, 2018, 57, 10507-10510.	4.0	43
9	Reactions of Medicinal Gold(III) Compounds With Proteins and Peptides Explored by Electrospray Ionization Mass Spectrometry and Complementary Biophysical Methods. Frontiers in Chemistry, 2020, 8, 581648.	3.6	43
10	Selection and characterization of a human ovarian cancer cell line resistant to auranofin. Oncotarget, 2017, 8, 96062-96078.	1.8	42
11	Ruthenium arene complexes with triphenylphosphane ligands: cytotoxicity towards pancreatic cancer cells, interaction with model proteins, and effect of ethacrynic acid substitution. New Journal of Chemistry, 2017, 41, 14574-14588.	2.8	37
12	A Fluorescent Silver(I) Carbene Complex with Anticancer Properties: Synthesis, Characterization, and Biological Studies. ChemMedChem, 2018, 14, 182-188.	3.2	35
13	Strategies for the Improvement of Metal-Based Chemotherapeutic Treatments. Biomedicines, 2021, 9, 504.	3.2	35
14	Structural Characterization of a Gold/Serum Albumin Complex. Inorganic Chemistry, 2019, 58, 10616-10619.	4.0	34
15	Mechanistic Insights Into the Anticancer Properties of the Auranofin Analog Au(PET3)I: A Theoretical and Experimental Study. Frontiers in Chemistry, 2020, 8, 812.	3.6	31
16	Mass spectrometry and metallomics: A general protocol to assess stability of metallodrug-protein adducts in bottom-up MS experiments. Talanta, 2017, 167, 30-38.	5.5	30
17	New Copper(II)/Cyclic Tetrapeptide System That Easily Oxidizes to Copper(III) under Atmospheric Oxygen. Inorganic Chemistry, 2007, 46, 10038-10040.	4.0	29
18	New gold carbene complexes as candidate anticancer agents. BioMetals, 2016, 29, 905-911.	4.1	29

#	ARTICLE	IF	CITATIONS
19	A focus on the biological targets for coinage metal-NHCs as potential anticancer complexes. Journal of Inorganic Biochemistry, 2021, 217, 111355.	3.5	29
20	Protein interactions of dirhodium tetraacetate: a structural study. Dalton Transactions, 2020, 49, 2412-2416.	3.3	29
21	Photocytotoxic Pt(IV) complexes as prospective anticancer agents. Dalton Transactions, 2019, 48, 10933-10944.	3.3	28
22	Two mixed valence diruthenium(II,III) isomeric complexes show different anticancer properties. Dalton Transactions, 2021, 50, 9643-9647.	3.3	28
23	Impact of ring size on the copper(II) coordination abilities of cyclic tetrapeptides. Journal of Inorganic Biochemistry, 2009, 103, 813-817.	3.5	26
24	New Pyrimido-Indole Compound CD-160130 Preferentially Inhibits the K <sub>V</sub> 1.1B Isoform and Produces Antileukemic Effects without Cardiotoxicity. Molecular Pharmacology, 2015, 87, 183-196.	2.3	26
25	Antiproliferative properties and biomolecular interactions of three Pd(II) and Pt(II) complexes. Journal of Inorganic Biochemistry, 2016, 165, 1-6.	3.5	26
26	The cisplatin/serum albumin system: A reappraisal. Inorganica Chimica Acta, 2019, 495, 118983.	2.4	26
27	A mixed-valence diruthenium(II,III) complex endowed with high stability: from experimental evidence to theoretical interpretation. Dalton Transactions, 2020, 49, 14520-14527.	3.3	25
28	{Ru(CO) <sub>x</sub> }-core complexes with selected azoles: Synthesis, X-ray structure, spectroscopy, DFT analysis and evaluation of cytotoxic activity against human cancer cells. Polyhedron, 2014, 81, 227-237.	2.2	24
29	The NAMI A “ human ferritin system: a biophysical characterization. Dalton Transactions, 2018, 47, 11429-11437.	3.3	24
30	Proteomics as a tool to disclose the cellular and molecular mechanisms of selected anticancer gold compounds. Coordination Chemistry Reviews, 2021, 438, 213905.	18.8	23
31	Short-chain oligopeptides with copper(II) binding properties: The impact of specific structural modifications on the copper(II) coordination abilities. Journal of Inorganic Biochemistry, 2009, 103, 678-688.	3.5	18
32	Anticancer Diiron Vinyliminium Complexes: A Structure–Activity Relationship Study. Pharmaceutics, 2021, 13, 1158.	4.5	18
33	The leading established metal-based drugs: a revisitation of their relevant physico-chemical data. BioMetals, 2019, 32, 813-817.	4.1	17
34	Dioxygen Oxidation Cu(II) → Cu(III) in the Copper Complex of cyclo(Lys-d-His- <sup>2</sup> Ala-His): A Case Study by EXAFS and XANES Approach. Inorganic Chemistry, 2012, 51, 7969-7976.	4.0	14
35	Alkyne Functionalization of a Photoactivated Ruthenium Polypyridyl Complex for Click-Enabled Serum Albumin Interaction Studies. Inorganic Chemistry, 2020, 59, 7710-7720.	4.0	14
36	Anticancer effects against colorectal cancer models of chloro(triethylphosphine)gold(I) encapsulated in PLGA–PEG nanoparticles. BioMetals, 2021, 34, 867-879.	4.1	13

#	ARTICLE	IF	CITATIONS
37	ESI-MS studies of the reactions of novel platinum(II) complexes containing O,O'-chelated acetylacetonate and sulfur ligands with selected model proteins. <i>BioMetals</i> , 2017, 30, 609-614.	4.1	12
38	Structural and solution chemistry, antiproliferative effects, and serum albumin binding of three pseudohalide derivatives of auranofin. <i>BioMetals</i> , 2019, 32, 939-948.	4.1	12
39	Protein metalation by two structurally related gold(I) carbene complexes: An ESI MS study. <i>Inorganica Chimica Acta</i> , 2021, 520, 120297.	2.4	12
40	Synthesis, DNA binding studies, and antiproliferative activity of novel Pt(II)-complexes with an L-alanyl-based ligand. <i>Journal of Inorganic Biochemistry</i> , 2020, 203, 110868.	3.5	11
41	On the Different Mode of Action of Au(I)/Ag(I)-NHC Bis-Anthracenyl Complexes Towards Selected Target Biomolecules. <i>Molecules</i> , 2020, 25, 5446.	3.8	11
42	Oxaliplatin inhibits angiogenin proliferative and cell migration effects in prostate cancer cells. <i>Journal of Inorganic Biochemistry</i> , 2022, 226, 111657.	3.5	11
43	Biotin Derivatives Carrying Two Chelating DOTA Units. Synthesis, in Vitro Evaluation of Biotinidases Resistance, Avidin Binding, and Radiolabeling Tests. <i>Journal of Medicinal Chemistry</i> , 2010, 53, 432-440.	6.4	9
44	When ferrocene and diiron organometallics meet: triiron vinyliminium complexes exhibit strong cytotoxicity and cancer cell selectivity. <i>Inorganic Chemistry Frontiers</i> , 2022, 9, 5118-5139.	6.0	9
45	Chlorido and bromido oxaliplatin analogues as potential agents for CRC treatment: Solution behavior, protein binding and cytotoxicity evaluation. <i>Inorganica Chimica Acta</i> , 2018, 470, 318-324.	2.4	8
46	Design and solid phase synthesis of new DOTA conjugated (+)-biotin dimers planned to develop molecular weight-tuned avidin oligomers. <i>Organic and Biomolecular Chemistry</i> , 2015, 13, 3988-4001.	2.8	7
47	Arsenoplatin-Ferritin Nanocage: Structure and Cytotoxicity. <i>International Journal of Molecular Sciences</i> , 2021, 22, 1874.	4.1	7
48	Thermodynamic Evaluation of the Interactions between Anticancer Pt(II) Complexes and Model Proteins. <i>Molecules</i> , 2021, 26, 2376.	3.8	7
49	Direct detection of iron clusters in L ferritins through ESI-MS experiments. <i>Dalton Transactions</i> , 2021, 50, 16464-16467.	3.3	6
50	Anti-Staphylococcal Activity of the Auranofin Analogue Bearing Acetylcysteine in Place of the Thiosugar: An Experimental and Theoretical Investigation. <i>Molecules</i> , 2022, 27, 2578.	3.8	6
51	Potent in vitro antiproliferative properties for a triplatinum cluster toward triple negative breast cancer cells. <i>Journal of Inorganic Biochemistry</i> , 2016, 163, 318-322.	3.5	5
52	Native mass spectrometry of human carbonic anhydrase I and its inhibitor complexes. <i>Journal of Biological Inorganic Chemistry</i> , 2020, 25, 979-993.	2.6	5
53	The first step of arsenoplatin-1 aggregation in solution unveiled by solving the crystal structure of its protein adduct. <i>Dalton Transactions</i> , 2021, 50, 68-71.	3.3	5
54	Role of the (pseudo)halido ligand in ruthenium(II)-cymene $\lambda^2$ -amino acid complexes in speciation, protein reactivity and cytotoxicity. <i>Dalton Transactions</i> , 2021, 50, 15760-15777.	3.3	5

#	ARTICLE	IF	CITATIONS
55	Protein-Based Delivery Systems for Anticancer Metallodrugs: Structure and Biological Activity of the Oxaliplatin/ $\beta^2$ -Lactoglobulin Adduct. <i>Pharmaceuticals</i> , 2022, 15, 425.	3.8	5
56	Synthesis of dicarba-cyclooctapeptide Somatostatin analogs by conventional and MW-assisted RCM: A study about the impact of the configuration at C $\beta$ of selected amino acids. <i>Chemical Engineering and Processing: Process Intensification</i> , 2017, 122, 365-372.	3.6	4
57	DOTA-Derivatives of Octreotide Dicarba-Analogs with High Affinity for Somatostatin sst <sub>2,5</sub> Receptors. <i>Frontiers in Chemistry</i> , 2017, 5, 8.	3.6	4
58	Editorial: The Golden Future in Medicinal Chemistry: Perspectives and Resources From Old and New Gold-Based Drug Candidates. <i>Frontiers in Chemistry</i> , 2021, 9, 665244.	3.6	4
59	Medicinal Hypervalent Tellurium Prodrugs Bearing Different Ligands: A Comparative Study of the Chemical Profiles of AS101 and Its Halido Replaced Analogues. <i>International Journal of Molecular Sciences</i> , 2022, 23, 7505.	4.1	3
60	Iron Binding in the Ferroxidase Site of Human Mitochondrial Ferritin. <i>Chemistry - A European Journal</i> , 2021, 27, 14690-14701.	3.3	2
61	Computationally enhanced X-ray diffraction analysis of a gold(III) complex interacting with the human telomeric DNA G-quadruplex. Unravelling non-unique ligand positioning. <i>International Journal of Biological Macromolecules</i> , 2022, 211, 506-513.	7.5	1
62	Ferritin-based anticancer metallodrug delivery: Encapsulation of Arsenoplatin-1 within the ferritin nanocage. , 0, , .		0